Compound tirzepatide for weight loss: separating real results from hype

What did @ashleytracks actually say?

Ashley described a three-month experience on compounded tirzepatide that started at 180.6 pounds and ended at 155, a loss of 25 pounds. She credited the medication with stopping more than a year of binge eating, reducing alcohol interest to near zero, and giving her what she called feeling "normal around things like food" for the first time in her life. She reported minimal side effects, uses WW's GLP-1 tracking feature, takes supplements proactively, and plans to eventually space doses to every two weeks for maintenance. She is transparent that she started on Lexapro before this, which she says triggered her binge eating disorder.

She is not claiming a cure. She is sharing a personal experience. That matters when reading the rest of this, because the line between "this happened to me" and "this will happen to you" is exactly where health misinformation lives, and she mostly stays on the right side of it.

Does the science back this up?

Most of it, yes, though the binge eating piece is still emerging and deserves more nuance than a TikTok caption can offer.

On weight loss, the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest dose producing an average 20.9% body weight reduction over 72 weeks. Ashley lost roughly 14% in 12 weeks, which is on the faster end but not implausible depending on starting dose and individual response.

On reduced food noise and compulsive eating, this is biologically real. GLP-1 and GIP receptors are expressed in areas of the brain involved in reward and compulsive behavior, and tirzepatide hits both. A 2023 study by Blundell et al. in Diabetes, Obesity and Metabolism found significant reductions in eating-related obsessional thinking on tirzepatide versus placebo.

On alcohol, the data is genuinely interesting. Rodrigues et al. (2023, Biological Psychiatry) and earlier rodent studies suggest GLP-1 receptor activation reduces dopamine reward signaling tied to alcohol consumption. Human trial data is limited but growing. Ashley's experience is consistent with what researchers are actively studying.

What did they get wrong (or right)?

She gets credit for intellectual honesty that most GLP-1 influencers skip. She named Lexapro as a potential trigger for her binge eating disorder, which is a documented if uncommon side effect of SSRIs and showed real self-awareness. She said explicitly "I know that's not the case for everybody." She did not claim the compound version is identical to Mounjaro or Zepbound. That matters, because it is not, and the FDA has flagged safety concerns about compounded tirzepatide specifically.

Where she falls short: she does not mention that compounded tirzepatide is currently in FDA regulatory limbo. In March 2024, the FDA declared tirzepatide no longer in shortage, which makes compounding it legally questionable as of this writing. She also says she had "minimal to zero side effects" without acknowledging that GI side effects affect a significant portion of users. The SURMOUNT-1 trial found nausea in roughly 30% of participants. Her experience is real. It is not representative.

The maintenance plan of spacing to every two weeks is not a standard clinical protocol and is not backed by controlled trial data. It may work. It may not. Presenting it as a likely path without that caveat is mildly misleading.

What should you actually know?

Three things matter here that Ashley did not cover, not because she was being dishonest, but because they fall outside a personal update video.

First, compounded tirzepatide is not the same as FDA-approved Zepbound or Mounjaro. The FDA has issued warnings about dosing errors and quality control issues with compounded versions. If you are considering this route, the regulatory status of your pharmacy and the prescribing oversight you are getting are not optional details.

Second, binge eating disorder is a clinical diagnosis and GLP-1 medications are not currently FDA-approved to treat it. There is real research interest here, including an ongoing trial (NCT05567536) examining semaglutide for BED specifically. But if someone is using a compounded drug sourced through a telehealth platform to manage a psychiatric condition that was triggered by another medication, that is a clinical situation requiring actual clinical supervision, not just an app and some supplements.

Third, the weight regain data after stopping GLP-1 therapy is consistent and significant. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that two-thirds of weight lost on semaglutide returned within a year of stopping. Ashley's plan to maintain on spaced doses is not unreasonable in spirit, but there is no trial data supporting every-two-week dosing for weight maintenance on tirzepatide specifically.

Bottom line

Ashley's video is one of the more grounded GLP-1 testimonials you will find on TikTok. The core claims about reduced food noise, alcohol interest, and weight loss are biologically plausible and consistent with published research. Her transparency about Lexapro, side effects, and individual variation is genuinely good health communication. The gaps are around compounding regulation, the clinical complexity of BED as a diagnosis, and the lack of long-term maintenance data. Those are not small gaps if someone is making a treatment decision based on this video.